The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

An analysis of a child health project reveals surprising factors in early-stage team success. When it comes to large research projects, strong leadership and experience may be a stronger predictor of ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Gilead Sciences, Inc. today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...

The haemorrhagic fever has now killed 11 people in Rwanda, with at least 25 more patients still fighting for their lives in ...

Gilead Sciences GILD underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely ...

For this we must commend the drug’s originator Gilead Sciences ... People who put their bodies on the line for science should be assured access to the fruits of that research.